-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

197 Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation (allo-HCT) Provides Durable Progression-Free Survival (PFS) in a Subset of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Relapsing after Autologous (auto-) HCTClinically Relevant Abstract

Clinical Allogeneic Transplantation: Results
Program: Oral and Poster Abstracts
Type: Oral
Session: 732. Clinical Allogeneic Transplantation: Results: Matched Related, Unrelated, and Alternative Donor Allograft Outcomes for Myeloid and Lymphoid Malignancies
Sunday, December 6, 2015: 8:30 AM
W304, Level 3 (Orange County Convention Center)

Timothy S. Fenske, MD, MS1*, Tara M. Graff, DO2*, Kwang Woo Ahn, PhD3,4*, Alyssa DiGilio, MS5*, Sonali M. Smith, MD6, Anna Sureda, MD, PhD7* and Mehdi Hamadani, MD8

1Division of Hematolgy and Oncology, Medical College of Wisconsin, Milwaukee, WI
2Medical Oncology Hematology Associates, Des Moines, IA
3CIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI
4Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI
5Department of Medicine, CIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI
6University of Chicago, Chicago, IL
7Institut Catalą d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain
8Division of Medicine, CIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI

Background: DLBCL relapsing after an auto-HCT has a poor prognosis. Unfortunately this is a common clinical dilemma, since ~50% of auto-HCTs for DLBCL ultimately fail. Allo-HCT is often considered following failure of an auto-HCT; however, limited information is available regarding prognostic factors identifying DLBCL patients likely to benefit from a subsequent allo-HCT. 

Methods: Adult (≥18 years) DLBCL patients undergoing an alloHCT between 2000-2012, after experiencing disease progression/relapse (P/R) following a prior autoHCT and reported to the CIBMTR were included. Patients undergoing tandem auto-allo HCT and those receiving allo-HCT for indications other than relapsed DLBCL were excluded. Primary outcomes were non-relapse mortality (NRM), P/R, PFS, and overall survival (OS). Cox regression method was used to develop a prognostic model of PFS and OS.

Results: Characteristics of 503 patients included in this analysis are shown in Table 1. The 3-yr univariate probabilities of NRM, P/R, PFS and OS were 30%, 38%, 31% and 37% respectively. Factors associated with higher NRM on multivariate analysis (MVA) included chemoresistance disease prior to allo-HCT (RR=1.86; p=0.003), myeloablative conditioning (MAC) (RR=1.99; p=0.0006; within 1st 10months following alloHCT) and unrelated donors (URD) grafts (RR=1.44; p=0.03).  Factors associated with P/R on MVA included chemoresistance (RR= 2.25, p<0.0001), Karnofsky performance status (KPS) <80 (RR 1.81, p=0.006), and interval between auto-HCT and allo-HCT of <1 yr (RR=2.28, p<0.0001).  Factors associated with inferior PFS on MVA included KPS <80 (RR=1.79, p=0.0005), chemoresistance (RR=2.04, p<0.0001), auto-HCT to allo-HCT interval <1 yr (RR=1.32, p=0.01), and MAC (RR 1.29, p=0.03). Factors associated with worse OS on MVA included KPS <80 (RR1.86, p=0.0003), chemoresistance (RR=1.94, p<0.0001), MAC (RR=1.39, p=0.008). Three adverse prognostic factors were used to construct a prognostic model for PFS, including; (i) KPS <80 (2 points) (ii) Interval between auto-HCT & allo-HCT of <1yr (1 point) and (iii) chemoresistant disease at allo-HCT (2 points). This CIBMTR prognostic model classified patients into three prognostic groups: low risk (0-1 points), intermediate risk (2-3 points), or high risk  (4-5 points), predicting 3-yr PFS probabilities of 38% (95% CI=32-44), 19% (95% CI=11-27) and 10% (95% CI=0-22), respectively (Fig 1). The 3-yr OS probabilities in similar order were 43%, 25% and 14% respectively.

Conclusion: The CIBMTR prognostic model identifies a subgroup of DLBCL patients relapsing from an auto-HCT who can experience long-term PFS following an allo-HCT.   Reduced-intensity conditioning is preferred in this setting.

Table1

N=503 (%)

Median age at alloHCT, years

52 (range 19-72)

Male gender

305 (61)

KPS ≥80

393 (78)

Stage III-IV at diagnosis

 54%

Rituximab prior to HCT

72%

Median lines of therapy

4 (range 1-7)

High LDH at HCT

 34%

Time from auto-HCT to allo-HCT, months

15 (range 1-198)

Disease status at transplant

 

CR

175 (35)

PR

197 (39)

Chemorefractory

106 (21)

Untreated

12 (2)

Missing

13 (3)

Type of donor

 

            Sibling

253 (50)

            URD

250 (50)

Myeloablative conditioning

127 (25)

PB graft

456 (91)

TBI in conditioning

133 (26)

Median follow up, months

55 (range 1-149)

Disclosures: Smith: Celgene: Consultancy ; Pharmacyclics: Consultancy . Sureda: Seattle Genetics Inc.: Research Funding ; Takeda: Consultancy , Honoraria , Speakers Bureau .

*signifies non-member of ASH